CytomX Therapeutics, Inc. Human Resources Contracts & Agreements

Employment Offer Letter Agreement between CytomX Therapeutics, Inc. and Jeffrey Landau dated as of March 31, 2021 (Filed With SEC on August 8, 2023)

Form of Amended and Restated Severance and Change of Control Agreement by and between CytomX Therapeutics, Inc. and each of its executive officers other than Sean A. McCarthy (Filed With SEC on August 8, 2023)

Separation Agreement effective as of September 30, 2022, by and between CytomX Therapeutics, Inc. and Alison Hannah, M.D (Filed With SEC on November 8, 2022)

Separation Agreement effective as of September 12, 2022, by and between CytomX Therapeutics, Inc. and Amy C. Peterson, M.D (Filed With SEC on November 8, 2022)

Separation Agreement effective as of September 30, 2022, by and between CytomX Therapeutics, Inc. and Carlos Campoy (Filed With SEC on November 8, 2022)

Consulting Agreement effective as of September 13, 2022, by and between CytomX Therapeutics, Inc. and Amy C. Peterson, M.D (Filed With SEC on November 8, 2022)

Consulting Agreement effective as of October 1, 2022, by and between CytomX Therapeutics, Inc. and Carlos Campoy (Filed With SEC on November 8, 2022)

Consulting Agreement, effective as of April 1, 2021, by and between CytomX Therapeutics, Inc. and Dr. Charles Fuchs (Filed With SEC on May 6, 2021)

Retirement Agreement by and between CytomX Therapeutics, Inc and Dr. W. Michael Kavanaugh, dated as of December 1, 2020 (Filed With SEC on February 24, 2021)

Consulting Agreement effective as of December 14, 2020, by and between CytomX Therapeutics, Inc and Dr. W. Michael Kavanaugh (Filed With SEC on February 24, 2021)

Severance and Change of Control Agreement dated March 23, 2020, by and between CytomX Therapeutics, Inc. and Carlos Campoy (Filed With SEC on May 7, 2020)

Employment Offer Letter Agreement between CytomX Therapeutics, Inc. and Carlos Campoy dated as of March 9, 2020 (Filed With SEC on May 7, 2020)

Severance and Change of Control Agreement effective as of February 3, 2020, by and between CytomX Therapeutics, Inc. and Alison Hannah, M.D (Filed With SEC on February 27, 2020)

2019 Employment Inducement Incentive Plan adopted on September 18, 2019 (2019 Plan) (Filed With SEC on November 7, 2019)

Employment Offer Letter Agreement between CytomX Therapeutics, Inc. and Amy C. Peterson, M.D. dated as of September 23, 2019 (Filed With SEC on November 7, 2019)

Consulting Agreement effective as of August 19, 2019, by and between CytomX Therapeutics, Inc. and Rachel W. Humphrey, M.D (Filed With SEC on November 7, 2019)

Severance and Change of Control Agreement effective as of October 14, 2019, by and between CytomX Therapeutics, Inc. and Amy C. Peterson, M.D (Filed With SEC on November 7, 2019)

Separation Agreement effective as of September 5, 2019, by and between CytomX Therapeutics, Inc. and Rachel W. Humphrey, M.D (Filed With SEC on November 7, 2019)

Amended and Restated Severance and Change of Control Agreement dated February 27, 2019, by and between CytomX Therapeutics, Inc. and Sean McCarthy. D. Phil (Filed With SEC on May 9, 2019)

Consulting Agreement effective as of May 15, 2019, by and between CytomX Therapeutics, Inc. and Debanjan Ray (Filed With SEC on May 9, 2019)

Amended and Restated Severance and Change of Control Agreement dated March 25, 2019, by and between CytomX Therapeutics, Inc. and Lloyd Rowland (Filed With SEC on May 9, 2019)

Amended and Restated Severance and Change of Control Agreement dated March 25, 2019, by and between CytomX Therapeutics, Inc. and Rachel W. Humphrey, M.D (Filed With SEC on May 9, 2019)

Amended and Restated Severance and Change of Control Agreement dated March 25, 2019, by and between CytomX Therapeutics, Inc. and Michael Kavanaugh, M.D (Filed With SEC on May 9, 2019)

Amended and Restated Severance and Change of Control Agreement dated March 25, 2019, by and between CytomX Therapeutics, Inc. and Debanjan Ray (Filed With SEC on May 9, 2019)

Consulting Agreement between CytomX Therapeutics, Inc and Dr. Hoyoung Huh, effective as of December 30, 2018 (Filed With SEC on February 27, 2019)

Severance and Change of Control Agreement, by and between CytomX Therapeutics, Inc. and Lloyd Rowland, dated as of May 16, 2018 (Filed With SEC on August 8, 2018)

SEPARATION AGREEMENT (Filed With SEC on August 7, 2017)

FIRST AMENDMENT TO SEVERANCE AND CHANGE OF CONTROL AGREEMENT (Filed With SEC on March 7, 2016)

CytomX Therapeutics, Inc. 2015 Equity Incentive Plan Option Award Notice (Filed With SEC on November 23, 2015)

CytomX Therapeutics, Inc. 2015 Equity Incentive Plan Early Exercise Option Award Notice (Filed With SEC on November 23, 2015)

CYTOMX THERAPEUTICS, INC. 2015 EQUITY INCENTIVE PLAN Adopted by Board: September 17, 2015 Approved by Stockholders: October 2, 2015 Termination Date: September 17, 2025 (Filed With SEC on October 6, 2015)

SEPARATION AGREEMENT AND GENERAL RELEASE OF CLAIMS (Filed With SEC on September 28, 2015)

CYTOMX THERAPEUTICS, INC. 2015 EQUITY INCENTIVE PLAN Adopted by Board: September 17, 2015 Termination Date: September 17, 2025 (Filed With SEC on September 28, 2015)

SEPARATION AGREEMENT AND GENERAL RELEASE OF CLAIMS (Filed With SEC on September 11, 2015)

SEPARATION AGREEMENT AND GENERAL RELEASE OF CLAIMS (Filed With SEC on August 28, 2015)

CYTOMX THERAPEUTICS, INC. STOCK OPTION AGREEMENT (2010 Stock Incentive Plan) (Filed With SEC on August 28, 2015)

2010 STOCK INCENTIVE PLAN CYTOMX THERAPEUTICS, INC. a Delaware corporation September 21, 2010 2010 STOCK INCENTIVE PLAN (Filed With SEC on August 28, 2015)

CYTOMX THERAPEUTICS, INC. 2011 STOCK INCENTIVE PLAN RESTRICTED STOCK AWARD AGREEMENT (Filed With SEC on August 28, 2015)

CYTOMX THERAPEUTICS, INC. 2011 STOCK INCENTIVE PLAN PREFACE (Filed With SEC on August 28, 2015)